Detailseite
Projekt Druckansicht

Krebszellenspezifische RNA-Interferenz in Vivo

Fachliche Zuordnung Pharmazie
Biologische und Biomimetische Chemie
Förderung Förderung von 2019 bis 2023
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 405833972
 
Erstellungsjahr 2023

Zusammenfassung der Projektergebnisse

Technology for suppression of gene expression by small interfering RNAs (siRNAs) led to several clinically approved drugs for metabolic diseases. However, there is still no practical solution for targeting pathological cells within normal tissue by siRNAs. Many disease-associated cells produce elevated levels of reactive oxygen species (ROS), e.g., in cancer and chronic granulomatous disease (CGD), that can be used for their targeting. Though ROS-activated carriers for siRNA delivery are known, they are based on sophisticated, heavily modified polymers and lipids. We developed in this project a simpler prodrug approach based on a minor chemical modification of guide strands of siRNAs with a 5’-O-(4-boronobenzyl)-phosphorothioate group, which is stable during RNA synthesis and under physiological conditions, but is cleaved in the presence of ROS to generate active siRNAs. We demonstrated ROS-responsive activation of the prodrugs for suppression of expression of kinesin family member 11 (KIF11) in vitro as well as initiation factor of protein translation (eEF2) and N-end ruledependent ubiquitin ligases Ubr1, Ubr2, Ubr4, Ubr5 eEF2 genes in vivo.

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung